Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XXB750 drug · 1 trial · 1 indication
To evaluate the efficacy and dose-response relationship of different doses of XXB750 compared to placebo in reducing the mean 24 hours ambulatory systolic blood pressure from baseline at Week 12. Automated arterial BP determinations and pulse rate readings were made with Microlife Watch BP Office 2G, an automated digital BP device. The primary outcome measure was evaluated using an optimally weighted contrast test following the Multiple Comparison Procedure-Modeling (MCP-MOD) methodology. There were five candidate models to capture the shape of the dose-response relationship for XXB750 at Week 12 endpoint. The outcome for the single best candidate model is shown in the Statistical Analysis section.
| Arm | Type | Description |
|---|---|---|
| Dose 1 | EXPERIMENTAL | Lowest dose |
| Dose 2 | EXPERIMENTAL | Dose 2 |
| Dose 3 | EXPERIMENTAL | Dose 3 |
| Dose 4 | EXPERIMENTAL | Highest dose |
| Dose 5 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| XXB750 drug | BIOLOGICAL | SC injection |
| Placebo | OTHER | SC injection |
Inclusion Criteria: 1. Male and female participants who are ≥ 18 years old. 2. Signed informed consent prior to participation in the study. 3. Apparent rHTN at screening (Visit 1) defined as uncontrolled BP with an office msSBP ≥ 140 mmHg despite treatment with stable (i.e., unchanged for ≥4 weeks)...
XXB750 is an investigational monoclonal antibody being developed for the treatment of resistant hypertension, a condition where blood pressure remains high despite treatment with multiple antihypertensive medications. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
XXB750 is being developed by Novartis AG, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol NVS. The company is conducting clinical trials to evaluate the drug's efficacy and safety in patients with resistant hypertension.
XXB750 is currently in Phase 2 clinical development. It has completed one Phase 2 trial, which was a randomized, double-blind, placebo-controlled study. The drug is still investigational and has not received regulatory approval for any indication.
XXB750 has been studied in one completed Phase 2 clinical trial, identified as NCT05562934. This trial was an efficacy, safety, tolerability, and dose-finding study conducted in patients with resistant hypertension, enrolling 189 participants across multiple countries including the United States, China, Japan, and several European nations.
No alternative names for XXB750 have been identified. The drug is known by its code name XXB750 and is being developed by Novartis AG. It is a monoclonal antibody intended for the treatment of resistant hypertension.